OverviewSuggest Edit

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company which develops and commercializes products in the therapeutic areas of allergy and respiratory disease. The Company's specialty pharmaceutical product candidates comprise pre-filled syringe for use in the emergency treatment of acute allergic reactions, and inhaler products for the treatment of bronchospasm, asthma and chronic obstructive pulmonary disease. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients.

TypePublic
Founded2006
HQSan Diego, US
Websiteadamispharmaceuticals.com

Latest Updates

Employees (est.) (Dec 2018)152(+41%)
Revenue (FY, 2019)$22.1 M(+47%)
Share Price (Sept 2020)$0.7 (-3%)
Cybersecurity ratingBMore

Key People/Management at Adamis Pharmaceuticals

Dennis J. Carlo

Dennis J. Carlo

Co-Founder & President, Chief Executive Officer, Director
Richard C. Williams

Richard C. Williams

Director
Robert O. Hopkins

Robert O. Hopkins

Vice President, Chief Financial Officer
David J. Marguglio

David J. Marguglio

Senior Vice President, Chief Business Officer, Co-Founder, Director
Ronald B. Moss

Ronald B. Moss

Chief Medical Officer
Thomas Moll

Thomas Moll

Vice President of Research
Show more

Adamis Pharmaceuticals Office Locations

Adamis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
11682 El Camino Real #300
Show all (1)

Adamis Pharmaceuticals Financials and Metrics

Adamis Pharmaceuticals Revenue

Adamis Pharmaceuticals's revenue was reported to be $22.11 m in FY, 2019
USD

Revenue (Q2, 2020)

3.9m

Gross profit (Q2, 2020)

(757.5k)

Gross profit margin (Q2, 2020), %

(19.3%)

Net income (Q2, 2020)

(11.3m)

EBIT (Q2, 2020)

(11.2m)

Market capitalization (23-Sept-2020)

67.4m

Closing stock price (23-Sept-2020)

0.7

Cash (30-Jun-2020)

7.9m

EV

64.8m
Adamis Pharmaceuticals's current market capitalization is $67.4 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

6.5m13.1m15.1m22.1m

Cost of goods sold

4.9m7.4m9.8m15.5m

Gross profit

1.6m5.7m5.3m6.6m

Gross profit Margin, %

25%43%35%30%
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.9m2.1m3.0m3.8m3.4m3.2m3.9m3.8m4.9m5.8m5.9m4.7m3.9m

Cost of goods sold

1.3m1.8m1.7m1.9m2.1m2.1m2.4m2.3m3.6m3.7m4.0m3.7m4.7m

Gross profit

582.1k254.5k1.4m1.9m1.3m1.1m1.5m1.5m1.3m2.1m1.9m976.2k(757.5k)

Gross profit Margin, %

30%12%45%51%38%35%39%40%26%36%32%21%(19%)
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

7.5k5.4m4.1m4.1m17.3m19.3m8.8m

Accounts Receivable

805.4k830.1k1.2m1.9m

Prepaid Expenses

31.5k64.3k14.5k71.0k474.2k2.1m1.1m

Inventories

942.1k1.8m3.3m2.1m
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

3.0k1.6k720.0k10.1k1.4k119.6k4.7m2.1m5.9m11.2m8.5m6.3m4.4m417.1k7.8m399.5k10.7m23.3m9.1m3.4m32.0m9.2m4.1m12.1m10.5m7.9m

Accounts Receivable

744.7k595.6k1.2m1.2m1.0m980.8k1.2m1.2m1.8m2.9m2.7m1.3m1.4m

Prepaid Expenses

238.1k117.2k83.6k61.4k104.3k76.0k46.2k67.3k567.4k170.8k265.3k206.2k215.2k209.9k543.5k391.0k1.3m3.1m2.1m1.0m1.0m607.5k

Inventories

1.2m1.1m914.2k950.0k996.1k2.3m2.6m3.2m3.4m2.9m2.5m2.5m2.1m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(4.9m)(7.2m)(8.2m)(13.6m)(19.4m)(25.5m)(39.0m)(29.3m)

Depreciation and Amortization

296.1k990.3k2.5m3.1m3.1m2.9m

Inventories

1.9k(882.5k)(5.0m)24.8k

Accounts Payable

757.5k411.2k(1.8m)(289.2k)(1.7m)587.2k846.1k574.5k
USDQ2, 2012

Financial Leverage

-0.2 x
Show all financial metrics

Adamis Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Adamis Pharmaceuticals Online and Social Media Presence

Embed Graph

Adamis Pharmaceuticals News and Updates

Thinking about buying stock in iBio Inc, Virgin Galactic, Sorrento Therapeutics, Adamis Pharmaceuticals, or Plug Power?

NEW YORK, Sept. 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, SPCE, SRNE, ADMP, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering

SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $6.7 million of its common stock …

Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe

SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that as of the close of business today, Adamis has not received any notice of action from the U.S. Food and Drug Administration (“FDA”) on the company’s New Drug Application re…

Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a business update.

Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update.

Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update

SAN DIEGO, March 15, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update.
Show more

Adamis Pharmaceuticals Blogs

Adamis Pharmaceuticals Provides Update on SYMJEPI Products

SAN DIEGO , July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020 , USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYMJEPI ® (epinephrine) Injection 0.3mg and SYMJEPI ® (epinephrine) Injection 0.15mg products through

Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose

SAN DIEGO , June 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu

Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

SAN DIEGO , June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license  to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19).  The license includes the worldwide use of Tempol for the

Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone

SAN DIEGO , May 27, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 ml of intramuscular

Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

SAN DIEGO , May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,

Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA

SAN DIEGO , May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its ZIMHI ™ (naloxone HCI Injection, USP) 5mg/0.5mL product candidate
Show more

Adamis Pharmaceuticals Frequently Asked Questions

  • When was Adamis Pharmaceuticals founded?

    Adamis Pharmaceuticals was founded in 2006.

  • Who are Adamis Pharmaceuticals key executives?

    Adamis Pharmaceuticals's key executives are Dennis J. Carlo, Richard C. Williams and Robert O. Hopkins.

  • How many employees does Adamis Pharmaceuticals have?

    Adamis Pharmaceuticals has 152 employees.

  • What is Adamis Pharmaceuticals revenue?

    Latest Adamis Pharmaceuticals annual revenue is $22.1 m.

  • What is Adamis Pharmaceuticals revenue per employee?

    Latest Adamis Pharmaceuticals revenue per employee is $145.5 k.

  • Who are Adamis Pharmaceuticals competitors?

    Competitors of Adamis Pharmaceuticals include Retrophin, Palatin Technologies and GBT (Global Blood Therapeutics).

  • Where is Adamis Pharmaceuticals headquarters?

    Adamis Pharmaceuticals headquarters is located at 11682 El Camino Real #300, San Diego.

  • Where are Adamis Pharmaceuticals offices?

    Adamis Pharmaceuticals has an office in San Diego.

  • How many offices does Adamis Pharmaceuticals have?

    Adamis Pharmaceuticals has 1 office.